Galectin Therapeutics (NASDAQ:GALT) Downgraded by StockNews.com to Sell
StockNews.com lowered shares of Galectin Therapeutics (NASDAQ:GALT – Free Report) from a hold rating to a sell rating in a research note published on Saturday. Separately, HC Wainwright reiterated a buy rating and set a $11.00 price objective on shares of Galectin Therapeutics in a research note on Friday, August 16th. Read Our Latest Analysis […]
2 Oct 05:33 · The Markets Daily